-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151

Benzinga·07/14/2026 11:39:18
语音播报
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.